title: [Experimental tests and clinical trials of the biologically active food additive Fibromed].
abstract: A biologically active food additive--Fibromed--has been tested experimentally and clinically. The additive made from wheat bran by the Reacon Company contains no less than 40% of dietary fibre (cellulose, hemicellulose and lignin). Its effect on multi-organ carcinogenesis induced by N-methyl-N-nitrosourea (MNU) and lipid metabolism was tested in rats. Tumors were induced by combined intramammary injections and intrarectal infusions of the agent. Fibromed was fed (20% by weight) during post-initiation period. It effectively inhibited the development of mammary and colonic tumors and reduced serum-blood cholesterol, triglycerides and beta-lipoproteids. The influence of Fibromed treatment on stool during early post-operative period was studied in surgical cases of colorectal cancer. When administered in a dose of 60 g, daily, starting from days 4-5, Fibromed restored intestinal function 36 hr earlier than in controls. Fibromed should be recommended for prevention of breast and colonic tumors, lipid metabolism disorders and rehabilitation of patients who underwent surgery for colorectal cancer.
authors.affiliation: N.N. Petrov Research Institute of Oncology, Ministry of the RF; St. Petersburg.
authors.forename: V G
authors.initials: VG
authors.lastname: Bespalov
authors.forename: A V
authors.initials: AV
authors.lastname: Aksenov
authors.forename: A I
authors.initials: AI
authors.lastname: Ovsianikov
authors.forename: A S
authors.initials: AS
authors.lastname: Petrov
authors.forename: N N
authors.initials: NN
authors.lastname: Simonov
authors.forename: V A
authors.initials: VA
authors.lastname: Aleksandrov
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000097:blood / Q000517:prevention & control*; D003110:Colonic Neoplasms / Q000097:blood / Q000517:prevention & control* / Q000601:surgery; D003248:Constipation / Q000209:etiology / Q000517:prevention & control*; D004043:Dietary Fiber / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000517:prevention & control*; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control; D051381:Rats; D016896:Treatment Outcome
chemical_list: D016588:Anticarcinogenic Agents; D004043:Dietary Fiber; D000960:Hypolipidemic Agents; D008055:Lipids
vernacular_title: Eksperimental'naia i klinicheskaia aprobatsiia biologicheski aktivnoĭ dobavki k pishche Fibromed.